News releases
Date
Language

Type of release


Download

Full announcement
Jan 21, 2013

Tresiba® and Ryzodeg® receive marketing authorisations in Europe

Bagsværd, Denmark, 21 January 2013 - Novo Nordisk today announced that the European Commission has granted marketing authorisations for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes in adults. The authorisations cover all 27 European Union member states.

Further information

Media:
Mike Rulis +45 4442 3573 mike@novonordisk.com
Ambre Morley (US) +1 609 216 5240 abmo@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 4442 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 4442 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Jannick Lindegaard (US) +1 609 786 4575 jlis@novonordisk.com

Company announcement No 6 / 2013